Search

OBJECTIVE: Glucagon-like peptide 1 receptor agonists (GLP-1RA) are widely used for the management of diabetes mellitus (DM), but their efficacy in familial partial lipodystrophy (FPLD) is unknown. In this retrospective study, we evaluated the effect of GLP-1RA in patients with FPLD. RESEARCH DESIGN AND METHODS: We analyzed data, reported with SDs, from 14 patients with FPLD (aged 58 ± 12 years; 76.47% female) and 14 patients with type 2 DM (aged 58 ± 13 years; 71% female) before and 6 months after starting GLP-1RA. RESULTS: We observed reduction in weight (95 ± 23 to 91 ± 22 kg; P = 0.002), BMI (33 ± 6 to 31 ± 6 kg/m2; P = 0.001), HbA1c (8.2% ± 1.4% to 7.7% ± 1.4%; P = 0.02), and fasting glucose (186 ± 64 to 166 ± 53 mg/dL; P = 0.04) in patients with FPLD. The change in triglycerides after treatment was greater in the FPLD group compared with the DM group (P = 0.02). We noted acute pancreatitis in two case subjects with FPLD with longer therapy. CONCLUSIONS: Our study demonstrates the relative safety and effectiveness of GLP-1RA in patients with FPLD. [ABSTRACT FROM AUTHOR]

This article discusses the use of a dual GIP/GLP-1 receptor agonist called tirzepatide in the treatment of two types of monogenic diabetes known as HNF1A-MODY and HNF4A-MODY. These forms of diabetes are caused by specific genetic variants and are typically treated with sulfonylurea or insulin. However, insulin can lead to hypoglycemia and weight gain. The article presents two case studies of individuals with HNF1A-MODY and HNF4A-MODY who were treated with tirzepatide. Both individuals experienced significant reductions in HbA1c levels and body weight, as well as a decrease in insulin dosage. The article suggests that tirzepatide may be a promising treatment option for individuals with these types of monogenic diabetes. Further research is needed to fully understand the mechanism of action and potential benefits of dual GIP/GLP-1 RA treatment in these conditions. [Extracted from the article]